Patchouli Oil (Pogostemon cablin)
Identity and Botanical Description
Patchouli (Pogostemon cablin) is a species of flowering plant in the family Lamiaceae, commonly called the mint or deadnettle family. The plant grows as a bushy perennial herb, with erect stems reaching up to 75 centimetres in height and bearing small, pale, pink-white flowers. It is native to the island region of Southeast Asia, including Sri Lanka, Indonesia, the Malay Peninsula, New Guinea, and the Philippines.
Pogostemon cablin, P. heyneanus and P. plectranthoides are all cultivated for their essential oil, known as patchouli oil. Although there are some sub-varieties, the most common commercial varieties are native to the islands of Sumatra and Sulawesi in Indonesia. The plant has also been widely cultivated in India and China for centuries as an aromatic and medicinal crop. Patchouli was initially recognized in 1845 by Pelletier-Sautelet.
Patchouli is a shrubby perennial plant that grows up to 1 metre in height. The large fragrant leaves are roughly oval in shape and irregularly toothed and are borne oppositely along the branching stems. Both the stems and the leaves are densely hairy. The small pale purple to white flowers are arranged in dense woolly spikes and have long stamens. The plants are commonly propagated from cuttings.
Common Names and Synonyms
- Scientific name: Pogostemon cablin (Blanco) Benth.
- Family: Lamiaceae
- Common names: Patchouli, patchouly, pachouli
- Known in China as guang huo-xiang, it is a long-time staple in traditional Chinese medicine for various indications, particularly gastrointestinal and skin disorders.
- It became known as "cabalam" in the Philippines.
Forms and Preparations
Patchouli essential oil is mainly obtained by steam distillation of the shade-dried leaves. Some sources say the highest-quality oil is produced from fresh, shade-dried biomass distilled close to where they are harvested; others say that boiling the dried leaves and fermenting them for a period of time is best.
Patchouli oil (PO) is available in crude patchouli oil (CPO) and fractionated forms, including light-fractionated (LFPO) and heavy-fractionated (HFPO), which differ in chemical composition and patchouli alcohol content, thereby influencing biological activity and stability.
Patchouli oil is encountered commercially in several forms:
- Crude essential oil — the unfractionated steam-distillate, used in perfumery and aromatherapy
- Fractionated oil — light and heavy fractions separated by vacuum distillation
- Dried leaf — used in herbal infusions and traditional preparations
- Microemulsions and nanoemulsion gels — emerging pharmaceutical delivery vehicles studied in preclinical settings
- The leaves can be made into an herbal tea for a variety of digestive ailments and are used as a moth repellent for clothing.
The main aim of cultivating this herb is to extract its oil, which is widely utilised in the manufacturing of cosmetics, fragrances, beverages, foods, and pharmaceuticals.
Traditional and Historical Use
Asian Origins
Patchouli essential oil is a product that originated and was popularized from Indian indigenous practice. Though the patchouli herb had been used for many centuries in Asian countries, it came to be appreciated in Europe only in the 1840s through its unique aroma associated with exported Indian fabrics. This led to the popularization of patchouli and extraction of its essential oil.
Patchouli has a longstanding historical use as a remedy for a wide range of health conditions, including colds, fevers, headaches, inflammation, digestive disorders, and insect and snake bites. In traditional Chinese medicine, patchouli is integral to formulations such as Pogostemon Herba and various pills, which are used for their anti-inflammatory properties. The medicinal applications of patchouli are widespread in countries such as China, Japan, and Malaysia, where it is used to treat ailments such as diarrhea, colds, headaches, and snake and insect bites.
In TCM, it is commonly used for treating gastrointestinal infectious disorders, including gastrointestinal cold, acute gastroenteritis, nausea, vomiting, and diarrhea. These conditions are believed to be linked to dampness and summer heat, as per the principles of TCM.
In traditional medicine, the oil is sometimes used topically to treat fungal skin infections, dandruff, and eczema, and is used in baths for rheumatism.
Trade Routes and Textile Use
During the early 1800s, it found use as an insect repellent for keeping bugs at bay while transporting garments from Asia to the rest of the world. The scent doubled up as a mark of authenticity for genuine eastern fabrics, such as silk around the time.
Aromatherapy and Modern Western Use
In aromatherapy, patchouli oil is used to relieve depression, stress, calm nerves, control appetite, and to improve sexual interest. The heavy, strong, woody, earthy, balsamic, and spicy scent of patchouli has been used for centuries in perfumes, and more recently in incense, insect repellents, chewing tobacco, and many alternative medicines. Patchouli oil is used widely in modern perfumery by individuals who create their own scents, as well as in modern scented personal products, such as bay rum, and industrial products, including paper towels, laundry detergents, and air fresheners.
Key Constituents and Chemical Composition
Overall Phytochemical Profile
More than 140 compounds, including terpenoids, phytosterols, flavonoids, organic acids, lignins, alkaloids, glycosides, alcohols, and aldehydes have been isolated and identified from patchouli. Patchouli leaf is distinguished by its rich profile of bioactive compounds, including terpenoids (monoterpenoids, sesquiterpenoids, and triterpenoids), flavonoids, lignins, phytosterols, organic acids, glycosides, aldehydes, alcohols, and pyrone.
Major Volatile Constituents
The main phytochemical compounds are patchouli alcohol, α-patchoulene, β-patchoulene, α-bulnesene, seychellene, norpatchoulenol, pogostone, eugenol, and pogostol.
Major constituents of the oils of aerial parts (leaves, inflorescence, and whole aerial parts) were patchouli alcohol (42.2–57.7%), α-bulnesene (9.0–15.2%), α-guaiene (6.4–17.9%), seychellene (3.4–6.9%), pogostol (0.3–5.0%) and (E)-caryophyllene (2.1–3.6%). However, the root oil was characterized by a higher amount of pogostone (70.2%), norpatchoulenol (5.3%), and β-pinene (4.5%).
Chemotypes
Due to variations in the secondary metabolites of volatile oil, the herb has been categorized into two distinct chemotypes, specifically Patchouliol and Pogostone. The Pogostone-type exhibits the presence of patchouliol, characterized by a relatively low proportion of non-oxygenated components, alongside pogostone, which displays a higher concentration of oxygenated components. The patchouliol-type exhibited a higher ratio of δ-guaiene, patchouliol, and α-guaiene, alongside an equivalent distribution of oxygenated as well as non-oxygenated constituents.
Non-Volatile Compounds
Using a column chromatography technique and spectral data, nine non-volatile chemical compounds were isolated from methanol leaf extracts of patchouli and identified as epifriedelinol, 5-hydroxymethyl-2-furfural, succinic acid, β-sitosterol, daucosterol, 3′′′-O-methyl-crenatoside, crenatoside, isocrenatoside, and apigenin-7-O-β-d-(6″-p-coumaryl)-glucoside.
Patchouli Alcohol: The Primary Bioactive Compound
Patchouli alcohol (PA), a tricyclic sesquiterpene, is a dominant bioactive component in oil extracted from the aerial parts of Pogostemon cablin. PA, being a sesquiterpene alcohol, is considered the most significant ingredient in patchouli oil. Patchouli alcohol is a primary component found in the oil and is employed as a quality indicator.
Established Mechanisms of Action
Anti-Inflammatory Mechanisms
Patchouli essential oil (PEO), patchouli alcohol (PA), pogostone (PO), and β-patchoulene (β-PAE) treatments provided an anti-inflammatory gut microenvironment in treated mice. Evidence included shifting the pro-inflammatory M1 macrophages to the anti-inflammatory M2 macrophages based on the expressions of M1 biomarkers (iNOS and CXCL 10) and M2 macrophage biomarkers (arginase 1). Pro-inflammatory cytokines, including IL-1β, IL-18, TNF-α, and Foxp3 were obviously reduced in the treated groups, echoing other reports in which LPS-induced pro-inflammatory cytokines TNF-α, IL-1β, iNOS, and IL-6 were inhibited by treatments with PA and PO.
Antiviral Mechanisms
Patchouli alcohol could inhibit influenza virus with an IC50 of 4.03 ± 0.23 µM. MTT assay showed that the inhibition by patchouli alcohol appears strongly after penetration of the virus into the cell. In an influenza mouse model, patchouli alcohol showed obvious protection against viral infection at a dose of 5 mg/kg/day. Flexible docking and molecular dynamic simulations indicated that patchouli alcohol was bound to the neuraminidase protein of influenza virus.
PA may block IAV infection through inactivating IAV directly and interfering with some early steps after virus adsorption. Cellular PI3K/Akt and ERK/MAPK signaling pathways may be involved in the anti-IAV actions of PA.
COX Inhibition
Virtual screening of compounds from patchouli oil using molecular docking tools concluded that alpha-patchouli alcohol is a potential inhibitor of the cyclo-oxygenase (COX)-1 enzyme. This is a preliminary computational finding that has not yet been confirmed in human clinical trials.
Gut Microbiota Modulation
PEO, PA, PO, and β-PAE improve the gut epithelial barrier by altering the status of E-cadherin vs. N-cadherin expressions, and increasing the mucosal p-lysozyme and Muc 2. Moreover, the treatments facilitate the polarization of M1 to M2 macrophage phenotypes, meanwhile suppressing pro-inflammatory cytokines.
Anti-Diarrheal Mechanisms
Research shows that patchoulol inhibits spontaneous contractions of colonic longitudinal smooth muscle in a concentration-dependent manner, with an EC50 of 41.9 µM. Additionally, patchoulol has proven effective in alleviating IBS-D symptoms in rat colon models. These findings indicate that patchoulol plays a key role in the anti-diarrheal effects of patchouli, although the exact pharmacological mechanisms remain to be elucidated.
Insect Repellency Mechanisms
Molecular docking showed key oil constituents binding to mosquito odorant-binding proteins (AaegOBP1 and AgamOBP1), with α-guaiene and β-elemene showing affinities comparable to DEET, suggesting a plausible olfactory disruption pathway.
Scientific Evidence by Area of Use
1. Antimicrobial Activity
Evidence strength: Preclinical (in vitro and in vivo); limited human data
In vitro antimicrobial tests of patchouli oil were studied by using molecular docking technology and antimicrobial testing. Five biological macromolecule enzymes required by bacteria in the process of biosynthesis were selected as target molecules. Six frequently-used pathogenic bacteria were selected for antimicrobial testing in vitro; patchouli oil and its two major compounds — (-)-patchouli alcohol and pogostone, which together exceeded 60% of patchouli oil content — were selected as antibacterial agents. Minimum inhibitory concentration (MIC) and minimum bactericidal concentration (MBC) were also determined. Molecular docking technology and in vitro antimicrobial testing proved that patchouli oil had strong antimicrobial effects.
The extracts, and important constituents (patchouli alcohol and pogostone) of the EO of P. cablin have been proved to be effective against many gram-positive and gram-negative bacteria, fungal species, particularly many strains of Candida albicans, and viral species.
Essential oils, including PO, have demonstrated broad-spectrum antibacterial, anti-inflammatory, and antibiofilm properties, with multi-component oils often showing superior efficacy compared with single-compound agents. However, despite promising in vitro results, the clinical and preclinical translation of essential oils has been limited by their inherent volatility, poor aqueous solubility, and susceptibility to oxidative, thermal, and photodegradation. No large-scale randomized human clinical trials on patchouli oil as a systemic antibiotic have been published.
2. Antifungal Activity
Evidence strength: Preclinical (in vitro and animal); no clinical trials in humans
Patchouli alcohol (44.52%) of the plant essential oil showed antifungal activity against a population of Aspergillus species.
A formulation of 1.5% light-fractionated patchouli oil (LFPO) demonstrated the strongest antifungal activity, producing a 31.18 ± 1.37 mm inhibition zone against M. globosa, surpassing ketoconazole (21.72 ± 0.28 mm), suggesting potential as a natural antifungal agent. Histological analysis in rabbits revealed that a 1.5% LFPO formulation reduced epidermal cell shedding, increased hair length by 41.6 ± 0.35 mm after six weeks, and promoted dense hair follicle growth. Despite these promising results, the efficacy and safety of LFPO formulations in humans remain unexplored, and a clinical human trial is necessary to assess skin tolerance, irritation risks, and long-term effects under real-world conditions.
Studies have reported antifungal activity of α-guaiene isolated from patchouli oil against four pathogenic fungi: Aspergillus niger, Candida albicans ATCC 7102, Microsporum gypseum ATCC 14683, and Trichophyton mentagrophytes ATCC 16404.
3. Anti-Inflammatory Effects
Evidence strength: Preclinical (animal models and in vitro); no human clinical trials
Patchouli alcohol (PA) has been most intensively studied in pharmacological effects including anti-inflammatory effect, anti-apoptotic effect, anti-oxidative effect, anti-tumor effect, and others.
The pharmacological impacts of the principal compounds include anti-peptic ulcer effect, antimicrobial effect, anti-oxidative effect, anti-inflammatory effect, effect on ischemia/reperfusion injury, analgesic effect, antitumor effect, antidiabetic effect, anti-hypertensive effect, immunoregulatory effect, and others. These are based on publications reviewed from PubMed, Web of Science, and related databases, and the vast majority involve preclinical models rather than human trials.
4. Antiviral Activity (Including Influenza)
Evidence strength: Preclinical (in vitro, animal, and in silico); no human clinical trials
The anti-influenza A (H2N2) virus activity of patchouli alcohol was studied in vitro, in vivo, and in silico. The CC50 of patchouli alcohol was above 20 µM. Patchouli alcohol could inhibit influenza virus with an IC50 of 4.03 ± 0.23 µM.
Oral administration of patchouli alcohol appeared to augment protection against influenza virus infection in mice via enhancement of host immune responses, and attenuation of systemic and pulmonary inflammatory responses. Patchouli alcohol also inhibited influenza A (H2N2) virus mainly through interfering with the functions of virus neuraminidase. All such studies are preclinical; no human trials have been conducted.
5. Gastrointestinal Effects
Evidence strength: Animal studies and preclinical; no published human clinical trials
Patchouli extracts have been shown to protect against gastrointestinal infection with Helicobacter pylori and ulcers; they can also suppress adipogenesis and fat accumulation in adipocytes, alleviate ischemia/reperfusion-induced brain injury, and prevent atherosclerosis. These findings are derived from animal and cell studies.
PEO, PA, PO, and β-PAE possess significant prebiotic-like effects in the C57BL/6J mouse model. The herbal treatments improved the gut epithelial barrier by reinstating the expressions of E-cadherin and N-cadherin, up-regulating p-lysozyme and Muc 2 genes expression, and suppressing pro-inflammatory cytokine expressions. 16S sequencing data showed that the herbal treatments positively modulated the gut microbiota composition, in which the relative abundance of SCFA-producing bacteria and LAP bacteria were enhanced while certain pathogenic bacteria were reduced.
6. Anxiolytic and Antidepressant Effects
Evidence strength: Animal studies; no rigorous human trials identified
A rat model of chronic unpredictable mild stress (CUMS) was constructed and the anxiolytic- and antidepressant-like effects of PCO were explored using the open field test (OFT) and forced swim test (FST). Results showed that CUMS induced an anxiety-like phenotype in the OFT, which was reversed by PCO, and that PCO also significantly mitigated the depression-like behaviors caused by CUMS in the FST. This is an animal study; results may not translate directly to humans.
7. Insect Repellent Activity
Evidence strength: Early human/semi-controlled studies and one 2026 formulation study; promising but limited
In a 2005 study by Trongtokit et al. of the mosquito-repellent activity of 38 essential oils at three concentrations (10%, 50%, or undiluted) against the mosquito Aedes aegypti under laboratory conditions using human volunteers, undiluted P. cablin oil was one of four oils to yield an effect, providing 2 hours of full repellency.
In ACS Omega, researchers described a patchouli oil-infused lotion that protected against mosquitoes as effectively as a commercially available DEET formulation. The formulation achieved complete protection against Aedes aegypti for up to three hours at a relatively low concentration of patchouli oil. Molecular docking showed key oil constituents binding to mosquito odorant-binding proteins (AaegOBP1 and AgamOBP1), with α-guaiene and β-elemene showing affinities comparable to DEET, suggesting a plausible olfactory disruption pathway.
In 2012, Wu et al. determined the acaricidal activity of compounds extracted from patchouli oil against the house dust mite (Dermatophagoides farinae). Overall, repellent research is still emerging; studies have been primarily conducted in laboratory settings.
8. Skin Conditions (Atopic Dermatitis, Dandruff)
Evidence strength: Preclinical animal studies; no large human trials
Patchouli oil (PO) is a natural substance notable for its immune-enhancing and anti-inflammatory effects. Atopic dermatitis (AD) is characterized by epidermal gene mutations, skin barrier dysfunction, and immune dysregulation, making patchouli volatile oil a potential candidate for AD treatment. The research is conducted in mouse models.
Patchouli EO is used for treating skin infections and is considered an excellent skin care agent because of its anti-inflammatory, antiseptic, antibacterial, antifungal and antiviral activities. Clinical human evidence specific to dermatological applications remains limited.
9. Anticancer Effects
Evidence strength: In vitro and animal only; no human trials
Diverse beneficial activities of patchouli alcohol have been reported, including anti-influenza virus, anti-depressant, anti-nociceptive, vasorelaxation, lung protection, brain protection, anti-ulcerogenic, anti-colitis, prebiotic-like, anti-inflammatory, anti-cancer, and protective activities against metabolic diseases. However, detailed mechanistic studies are required to explore the possibility of developing PA as a functional food material or promising drug for the prevention and treatment of human diseases. All anticancer findings are from cell lines or rodent models.
Body Systems and Health Areas Associated with Patchouli Oil
- Gastrointestinal system: TCM and traditional Ayurvedic use for diarrhea, nausea, vomiting, gastroenteritis; preclinical evidence for gut barrier protection and microbiota modulation
- Immune system: Macrophage polarization effects and cytokine modulation shown in rodent studies
- Integumentary system (skin): Topical traditional use for fungal infections, eczema, and dermatitis; preclinical support for anti-inflammatory and antifungal properties
- Respiratory system: Traditional use for colds and fever; preclinical antiviral evidence against influenza strains
- Central nervous system/mood: Aromatherapy use for stress, anxiety, and depression; animal evidence for anxiolytic effects; no confirmed human trials
- Cardiovascular system: Antiplatelet and antithrombotic activities noted in review literature as preclinical findings
- Metabolic health: Preclinical evidence for anti-adipogenic effects
Dosage Forms and Dosages Reported in Studies
Human clinical dosage data for patchouli oil as a dietary supplement or medicinal agent is sparse. The following figures are drawn from preclinical or semi-controlled studies as reported in source literature:
- In an influenza mouse model, patchouli alcohol showed obvious protection against viral infection at a dose of 5 mg/kg/day.
- In a gut microbiota study, C57BL/6J mice were treated with PEO and three active components of PEO — patchouli alcohol (PA), pogostone (PO), and β-patchoulene (β-PAE) — for 15 consecutive days.
- In a hair and scalp study, a formulation of 1.5% LFPO demonstrated the strongest antifungal activity against M. globosa.
- A patchouli oil microemulsion gel (PO-MEG) was developed with a specified concentration of 1.5% carbomer-940 as the matrix for preclinical atopic dermatitis study.
- In the Trongtokit et al. mosquito-repellent study, concentrations of 10%, 50%, or undiluted were tested; undiluted P. cablin oil provided 2 hours of full repellency.
- For aromatherapy uses, no standardized clinical dosing protocol has been established in peer-reviewed human trials.
Safety Considerations and Interactions
General Safety
Much of the evidence for the benefits of patchouli oil is anecdotal. Some promising research is beginning to show that it may have anti-inflammatory, antimicrobial, and pain-relieving properties, but further research is necessary to confirm any of these claims.
Skin and Topical Use
Like many essential oils, there is a risk of irritation when applying patchouli oil to skin. However, diluted, lower concentrations of patchouli are likely fine for most individuals.
Standard safety data sheets for patchouli oil note that it causes skin irritation, may cause an allergic skin reaction, and causes serious eye irritation.
Regulatory and Fragrance Industry Standards
The IFRA Standards regarding use restrictions are based on safety assessments by the Panel of Experts of the Research Institute for Fragrance Materials (RIFM) and are enforced by the IFRA Scientific Committee. Patchouli oil is evaluated under these standards for use in consumer products across multiple categories, with concentration limits varying by product type and application site.
Antiplatelet and Anticoagulant Potential
Modern studies have revealed biological activities including antiplatelet and antithrombotic activities. These effects, identified in preclinical work, raise a theoretical concern about interactions with anticoagulant medications, but no human pharmacokinetic or drug-interaction studies have been published to date.
Evidence Gaps and Limitations
Despite robust traditional knowledge, specific therapeutic applications of patchouli leaves require scientific validation and standardization of their bioactive compounds.
Some of the traditional uses need to be verified and may require standardizing and authenticating the bioactivity of purified compounds through scientific methods.
Despite promising in vitro results, the clinical and preclinical translation of essential oils has been limited by their inherent volatility, poor aqueous solubility, and susceptibility to oxidative, thermal, and photodegradation.
The overwhelming weight of current patchouli oil pharmacological research consists of in vitro and rodent studies. As of the current literature, there is an absence of large-scale, placebo-controlled human clinical trials evaluating efficacy and safety for any specific therapeutic indication. Traditional use data is documented across multiple Asian medical systems, but this does not constitute proof of efficacy by contemporary evidence-based medicine standards.
References
Go back